EFG
FBLG icon

Ethos Financial Group’s FibroBiologics FBLG Stock Holding History

Ethos Financial Group’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,221
Closed -$5.49K – 568
2025
Q4 		$5.49K Hold
1,221
– – ﹤0.01% 523
2025
Q3 		$13.3K Sell
1,221
-1,221
-50% -$14.6K ﹤0.01% 499
2025
Q2 		$64K Buy
2,442
+1,221
+100% +$22K 0.01% 455
2025
Q1 		$48.8K Hold
1,221
– – ﹤0.01% 433
2024
Q4 		$48.8K Sell
1,221
-52
-4% -$2.79K 0.01% 345
2024
Q3 		$79K Hold
1,273
– – 0.01% 291
2024
Q2 		$127K Buy
+1,273
New +$243K 0.02% 273

Other funds holding FBLG

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Ethos Financial Group's FBLG Position: Q1 2026 in Review

Ethos Financial Group sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 1,221 shares — an estimated $5.49K sold.

Ethos Financial Group first reported a position in FBLG in Q2 2024 and held it in 7 quarters. The position peaked at $127K in Q2 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Ethos Financial Group reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
  • Ethos Financial Group sold 1,221 FibroBiologics shares in Q1 2026, an estimated $5.49K.
  • Ethos Financial Group first reported a position in FibroBiologics in Q2 2024 and held it in 7 quarters.
  • Ethos Financial Group's FibroBiologics position peaked at $127K in Q2 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Ethos Financial Group's 13F filing for Q1 2026, filed 5 May 2026.